Dr. Wang on Comparative Analysis of KTE-X19 in Higher- Versus Lower-Risk R/R MCL

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the objectives of a comparative analysis of the phase 2 ZUMA-2 trial with KTE-X19 in patients with mantle cell lymphoma (MCL).

In the MCL space, investigators have recently developed the CD19-targeted CAR T- cell therapy KTE-X19, says Wang. At the 2019 ASCO Annual Meeting, investigators presented exciting data with this product in patients with relapsed disease, Wang adds. Notably, at the time, the primary safety and efficacydata from the trial were reported.

In the analysis reported at the 2020 ASCO Virtual Scientific Program, investigators are reporting on the same population of patients with relapsed/refractory MCL who received 1-5 prior lines of BTK inhibitor therapy, Wang explains. However, with this analysis, investigators reported on pharmacological data, such as T-cell expansion, T-cell differentiation, cytokine changes, and several other characteristics in patients with higher versus lower-risk disease, concludes Wang.